Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

of Vascular Diseases and Surgery. "This clinical trial represents a unique opportunity to evaluate a novel biologic treatment for 'no-option' CLI patients and reinforces Ohio State Medical Center's leadership role in the clinical evaluation of these important technologies to improve the delivery of care for our patients."

Ultimately, Arteriocyte expects this technology to benefit many of the 750,000 individuals suffering from Critical Limb Ischemia in the United States. CLI is caused by a severe blockage of peripheral arteries that significantly impairs blood flow to the extremities, causing chronic tissue degeneration and necrosis. It is estimated that 150,000 individuals lose a limb due to this disease each year(1).

Arteriocyte's Chief Executive Officer, Don Brown shared, "We're thrilled to have the green light to initiate this next important step in the clinical development program for the Magellan MAR01™ technology. It represents yet another achievement in our public-private partnership with Ohio's Third Frontier Program, and their support of our development of Magellan based cellular therapies for the treatment of cardiovascular and critical limb ischemia patients."

About Arteriocyte

Arteriocyte, a leading clinical stage biotechnology company, is dedicated in developing novel stem cell products and medical devices for unmet research and clinical needs. Arteriocyte leverages its expertise in stem cell and tissue engineering in order to develop a broad portfolio of cell based therapeutics to improve patient outcomes. In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to address serious unmet medical needs in cardiac, orthopedic and vascular surgeries. Today, Arteriocyte Medical Systems manufactures and distributes the Magellan® Autologous Plat
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 Lighthouse Information Systems, Inc., ... in California, Oregon, Washington and clients across the ... and Acquisition (M&A) Integration Services offering, effective immediately. ... Services and M&A Integration Practice Leader at Lighthouse, ... majority of M&A initiatives fail to achieve their ...
(Date:3/30/2015)... , March 30, 2015  Multiple new research abstracts ... several important health factors. From their impact on colon ... positive effect on both gut health and vascular health, ... detail our latest understanding of walnuts, inner workings. Running ... , this annual meeting attracts an international audience ...
(Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4
... Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty,biopharmaceutical company, will ... Results press release will be issued at: ... Investor meeting and conference call time: 14:30 BST ... conference call:, Angus Russell, Chief Executive Officer, Graham ...
... July 3 Cellectis SA today,announced the signature ... use of Cellectis, patents covering certain uses of ... including,the development of fully human monoclonal antibodies. As ... of 12,450,000$ from Regeneron.,In addition, Regeneron will invest ...
... Inc. and Isis,Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... and OncoGenex has elected to independently,develop its lead ... solely responsible for all future development activities,costs and ... longer be,responsible for funding 35% of development costs, ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology 2OncoGenex increases economic interest in lead cancer drug OGX-011 2OncoGenex increases economic interest in lead cancer drug OGX-011 3OncoGenex increases economic interest in lead cancer drug OGX-011 4
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... 12, 2015 The mascots of the Atlantic ... part of Wake Forest Baptist Medical Center. They stopped ... 2015 ACC Men,s Basketball Tournament. Young patients enjoyed bonding ... getting their autographs. Brenner Children,s Hospital is ... the only children,s hospital in northwest North ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Northwestern Medicine scientists have identified a component ... cells, allowing the virus to rapidly and successfully ... Led by Gregory Smith, associate professor in immunology ... Medicine, researchers found that viral protein 1-2, or ...
... carry an abundance of bacteria on their surfaces, not all ... the variety of these non-pathogenic bacteria, scientists report that these ... cultivation practices. The results are published March 27 in the ... and Noah Fierer at the University of Colorado, Boulder. ...
... of Medicine at Mount Sinai is leading an international team ... to gain a better understanding of Alzheimer,s disease (AD). As ... Noggle, PhD, the NYSCF Charles Evans Senior Research Fellow ... Cell Foundation (NYSCF),s laboratory in Manhattan. Dr. Gandy heads ...
Cached Biology News:How herpesvirus invades nervous system 2Mount Sinai leads global program using stem cells to accelerate cures for Alzheimer's disease 2
... LiCl precipitation offers major advantages over other RNA ... DNA, protein or carbohydrates. It is the method ... cDNA synthesis from RNA preparations. Note, LiCl precipitation ... RNA isolations. If the RNA is to be ...
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: